| | | | | |
|---|
| PART I | | FINANCIAL INFORMATION | | 5 |
|---|
| | | | | |
|---|
| Item 1 | | Condensed Consolidated Financial Statements | | 5 |
|---|
| | | | | |
|---|
| | | Condensed Consolidated Balance Sheets (Unaudited) | | 5 |
|---|
| | | | | |
|---|
| | | Condensed Consolidated Statements of Operations (Unaudited) | | 6 |
|---|
| | | | | |
|---|
| | | Condensed Consolidated Statements of Comprehensive Loss (Unaudited) | | 7 |
|---|
| | | | | |
|---|
| | | Condensed Consolidated Statements of Stockholders’ Equity (Unaudited) | | 8 |
|---|
| | | | | |
|---|
| | | Condensed Consolidated Statements of Cash Flows (Unaudited) | | 10 |
|---|
| | | | | |
|---|
| | | Notes to Condensed Consolidated Financial Statements (Unaudited) | | 11 |
|---|
| | | | | |
|---|
| Item 2 | | Management’s Discussion and Analysis of Financial Condition and Results of Operations | | 29 |
|---|
| | | | | |
|---|
| Item 3 | | Quantitative and Qualitative Disclosures About Market Risk | | 39 |
|---|
| | | | | |
|---|
| Item 4 | | Controls and Procedures | | 39 |
|---|
| | | | | |
|---|
| PART II | | OTHER INFORMATION | | 40 |
|---|
| | | | | |
|---|
| Item 1 | | Legal Proceedings | | 40 |
|---|
| | | | | |
|---|
| Item 1A | | Risk Factors | | 40 |
|---|
| | | | | |
|---|
| Item 2 | | Unregistered Sales of Equity Securities and Use of Proceeds | | 40 |
|---|
| | | | | |
|---|
| Item 3 | | Defaults Upon Senior Securities. | | 41 |
|---|
| | | | | |
|---|
| Item 4 | | Mine Safety Disclosures | | 41 |
|---|
| | | | | |
|---|
| Item 5 | | Other Information | | 41 |
|---|
| | | | | |
|---|
| Item 6 | | Exhibits | | 42 |
|---|
| | | | | |
|---|
| Signatures | | 43 | |
|---|
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS
This Quarterly Report on Form 10-Q (the “Quarterly Report”) contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). These forward-looking statements can be identified by the fact that they do not relate strictly to historical or current facts and are often characterized by the use of words such as “aim,” “believe,” “can,” “could,” “potential,” “plan,” “predict,” “goals,” “seek,” “should,” “may,” “may have,” “would,” “estimate,” “continue,” “anticipate,” “intend,” “expect” or the negative of these terms, other comparable terminology or by discussions of strategy, plans or intentions. These include, but are not limited to, statements about:
| ● | our ability to continue as a going concern and our needs for additional financing; |
| ● | our ability to maintain compliance with the continued listing requirements of the Nasdaq Stock Market LLC (“Nasdaq”); |
| ● | our ability to accurately estimate anticipated operating losses, expenses, future revenues, capital requirements, including our anticipated cash runway; |
| ● | the initiation, timing, progress and results of our current and future preclinical studies and clinical trials and our research and development programs; |
| ● | the success of our efforts to expand our pipeline of product candidates and develop marketable products through the use of our Magellan™ platform; |
| ● | our ability to develop, obtain regulatory approval for and commercialize our current and future product candidates; |
| ● | our expectations regarding collaborations and other agreements with third parties and their potential benefits; |
| ● | the timing of investigational new drug, or IND, submissions, initiation of preclinical studies and clinical trials, and timing of expected clinical results for our product candidates; |
| ● | our success in early preclinical studies, which may not be indicative of results obtained in later studies or clinical trials; |
| ● | the potential benefits of our product candidates; |
| ● | our ability to identify patients with the diseases treated by our product candidates, and to enroll healthy volunteers and patients in clinical trials; |
| ● | our ability to obtain, maintain and protect our intellectual property; |
| ● | our reliance upon intellectual property licensed from third parties, including the license to use certain components of the Magellan™ platform; |
| ● | our ability to identify, recruit and retain key personnel; |
| ● | developments or projections relating to our competitors or our industry; |
| ● | the impact of laws and regulations; |
| ● | our expectations regarding government and third-party payor coverage and reimbursement; |
| ● | our expectations regarding the time during which we will be an emerging growth company under the Jumpstart Our Business Startups (“JOBS”) Act; |
| ● | the impact of liquidity concerns at and failures of banks and other financial institutions, capital market instability, exchange rate fluctuations, supply chain disruptions and increases in commodity, energy and fuel prices; |
| ● | the impacts of pandemics or endemics on our operations, access to capital, research and development and clinical trials and potential disruption in the operations and business of third-party manufacturers, contract research organizations, other service providers, and collaborators with whom we conduct business; |
| ● | the impact of other global events, including political instability, natural disaster, events of terrorism and wars, including the war between Ukraine and Russia, and the corresponding tensions created from such conflict between Russia, the United States and countries in Europe as well as other countries such as China; and the conflict between Hamas and Israel; |
| ● | the impacts of changes to international trade policy, including tariff and customs regulations; and |
| ● | other factors and assumptions described in this Quarterly Report. |
You should read this Quarterly Report with the understanding that such forward-looking statements involve known and unknown risks, expectations, uncertainties, assumptions, estimates and projections about our company and other important factors that could cause our actual results, performance or achievements, actual industry results, or other actual results or events to differ materially from historical results, from any plans, intentions, or expectations disclosed in such forward-looking statements or from any future results, performance, achievements or other events expressed, suggested or implied by such forward-looking statements. Therefore, you should not rely on any forward-looking information or statements as predictors of future results or events. Factors that could cause or contribute to such differences in results and events include, without limitation, those specifically addressed under the headings “Risk Factors” and “Management’s Discussion and Analysis of Financial Conditions and Results of Operations” in this Quarterly Report and in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024 (“Annual Report”) filed with the Securities and Exchange Commission (“SEC”) on March 27, 2025. The effect of these factors is difficult to predict. In addition, factors other than these could also adversely affect our results, and the reader should not consider these factors to be a complete set of all potential risks or uncertainties. New factors emerge from time to time, and management cannot assess the impact of any such factor on our business or the extent to which any factor, or combination of factors, may cause results or events to differ materially from those contained in any forward-looking statements.
Any forward-looking statements included herein speak only as of the date of this Quarterly Report, and we undertake no obligation to update any forward-looking information or statements for any reason after the date of this Quarterly Report to conform these statements to actual results or changes in expectations, except as required by law. All forward-looking statements attributable to us are expressly qualified by the foregoing cautionary statements.
